Table 2.
Anti-ZIKV microneutralization test (MNT) antibody prevalence in 2007 and in 2011/2012 in Mali, Senegal and The Gambia, by age group and sex (%, 95%CI).
| Study Site | Bamako, Mali | Niakhar, Senegal | Basse Santa Su, The Gambia | ||||
|---|---|---|---|---|---|---|---|
| Year of Collection | 2007 %(95%CI) |
2011/2012 % (95%CI) |
2007 % (95%CI) |
2011/2012 % (95%CI) |
2007 % (95%CI) |
2011/2012 % (95%CI) |
|
| Age | 2–10 y | 0.0 (0.0–3.73) |
0.0 (0.0–4.2) |
1.2 (0.03–6.31) |
2.3 (0.28–8.06) |
0.0 (0.0–3.69) |
0.0 (0.0–4.35) |
| 11–17 y | 0.0 (0.0–3.85) |
0.0 (0.0–4.93) |
15.7 (9.24–24.22) |
22.7 (13.79–33.79) |
2.0 (0.25–7.11) |
7.6 (2.51–16.8) |
|
| 18–29 y | 1.0 (0.03–5.45) |
1.4 (0.04–7.81) |
21.9 (14.08–31.47) |
20.4 (10.24–34.34) |
9.1 (4.24–16.56) |
16.1 (8.02–27.67) |
|
| Sex | M | 0.6 (0.01–3.22) |
0.8 (0.02–4.28) |
12.0 (7.4–18.14) |
11.7 (6.39–19.19) |
3.4 (1.24–7.15) |
7.8 (3.81–13.9) |
| F | 0.0 (0.0–3.03) |
0.0 (0.0–3.62) |
15.1 (9.33–22.54) |
16.0 (9.43–24.68) |
4.3 (1.4–9.69) |
6.0 (1.98–13.5) |
|
| Total | 0.3 (0.01–1.90) |
0.4 (0.01–2.42) |
13.4 (9.65–17.9) |
13.7 (9.4–19.14) |
3.7 (1.87–6.55) |
7.1 (4.03–11.45) |
|